Daniel Skovronsky
Daniel Skovronsky is the Chief Scientific Officer at Eli Lilly and has been instrumental in advancing diabetes and obesity treatments. He recently highlighted the potential impact of a new oral GLP-1 medication, orforglipron, which could revolutionize treatment for millions suffering from type 2 diabetes and obesity.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Liechtenstein:
Daniel Skovronsky, the scientific director of Lilly, stated that injections cannot be the solution for billions of people around the world.
7